Salt: Zanamivir
Therapeutic Description: Antivirals, Systemics
Category: Neuraminidase inhibitor.
Pregnancy: Risk cannot be ruled out.
Lactation: Contraindicated or not recommended.
Precautions: Warn patients with asthma or COPD of bronchospasm risk and need for fast acting bronchodilator to be on hand. Risk of neuropsychiatric events; monitor patients for behavioural changes and evaluate risk: benefit of continuing treatment for each patient.
Treatment and prevention of influenza A and B when the virus is in the community.
Treatment: Adults: 2 inhalations twice daily for 5 days starting within 48 hours of onset of symptoms.
Post-exposure prophylaxis: Adults: 2 inhalations once daily for 10 days starting within 36 hours of onset of symptoms.
Seasonal prophylaxis: Adults: 2 inhalations once daily for up to 28 days.
Rarely, acute bronchospasm, decline in respiratory function (withdraw immediately), facial and oropharyngeal oedema, rash, urticaria. Reports of convulsions and psychiatric events (e.g., depressed level of consciousness, abnormal behaviour, hallucinations and delirium).
Strength Pack Size PKR
5 mg20's1600.00

Your medicine formula resulted in the following types of medicine type. Please select to proceed.